107 related articles for article (PubMed ID: 23746182)
1. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.
Verhoef TI; Redekop WK; Veenstra DL; Thariani R; Beltman PA; van Schie RM; de Boer A; Maitland-van der Zee AH;
Pharmacogenomics; 2013 Jun; 14(8):869-83. PubMed ID: 23746182
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.
Verhoef TI; Redekop WK; de Boer A; Maitland-van der Zee AH;
Pharmacogenomics; 2015 Jan; 16(2):101-14. PubMed ID: 25616097
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
Patrick AR; Avorn J; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
Eckman MH; Rosand J; Greenberg SM; Gage BF
Ann Intern Med; 2009 Jan; 150(2):73-83. PubMed ID: 19153410
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.
You JH
Pharmacogenet Genomics; 2014 Jan; 24(1):6-14. PubMed ID: 24168919
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.
Kim DJ; Kim HS; Oh M; Kim EY; Shin JG
Appl Health Econ Health Policy; 2017 Oct; 15(5):657-667. PubMed ID: 28247199
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.
Verhoef TI; Redekop WK; Langenskiold S; Kamali F; Wadelius M; Burnside G; Maitland-van der Zee AH; Hughes DA; Pirmohamed M
Pharmacogenomics J; 2016 Oct; 16(5):478-84. PubMed ID: 27272045
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
9. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.
Mitropoulou C; Fragoulakis V; Bozina N; Vozikis A; Supe S; Bozina T; Poljakovic Z; van Schaik RH; Patrinos GP
Pharmacogenomics; 2015 Jan; 16(2):137-48. PubMed ID: 25616100
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
Leey JA; McCabe S; Koch JA; Miles TP
Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand.
Chong HY; Saokaew S; Dumrongprat K; Permsuwan U; Wu DB; Sritara P; Chaiyakunapruk N
Thromb Res; 2014 Dec; 134(6):1278-84. PubMed ID: 25456732
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
[TBL] [Abstract][Full Text] [Related]
15. Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.
Tang T; Liu J; Zuo K; Cheng J; Chen L; Lu C; Han S; Xu J; Jia Z; Ye M; Pei E; Zhang X; Li M
J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):387-94. PubMed ID: 25575537
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.
Verhoef TI; Redekop WK; van Schie RM; Bayat S; Daly AK; Geitona M; Haschke-Becher E; Hughes DA; Kamali F; Levin LÅ; Manolopoulos VG; Pirmohamed M; Siebert U; Stingl JC; Wadelius M; de Boer A; Maitland-van der Zee AH;
Pharmacogenomics; 2012 Sep; 13(12):1405-17. PubMed ID: 22966889
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.
Martes-Martinez C; Méndez-Sepúlveda C; Millán-Molina J; French-Kim M; Marín-Centeno H; Rivera-Miranda GC; Hernández-Muñoz JJ; Duconge-Soler J
P R Health Sci J; 2017 Sep; 36(3):165-172. PubMed ID: 28915306
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
